EDIT: Editas Medicine Inc Market Price to Net Income Ratio

Symbol and logo of brand Editas (EDIT)

Editas Medicine, Inc. (EDIT) maintains its research centers in Massachusetts, while the scaling of drug production relies on US bio-factories. Neutral geopolitics and protection from sanctions provide a stable backdrop for scientific advancement. This price action for the securities on GURU.Markets illustrates a P/E ratio of -3.90, while ownership of key CRISPR patents enables the company to develop unique blood treatment methods.

Editas Medicine (EDIT): Price to Earnings Ratio from 07/04/2022 to 11/18/2026

Analytical breakdowns for Editas Medicine, Inc.

- market value and analyst target forecast:
- market capitalization information:
Summary company analysis:EDIT (Editas Medicine)
Flagship merchandise of Editas Medicine, Inc.

The long-term reliability of Editas Medicine, Inc. (EDIT) is based on the exclusivity of its CRISPR technologies and high barriers to entry for competitors. The P/E metric determines the business value relative to its net income, reflecting the market valuation of every dollar earned. By analyzing the issuer's P/E ratio, an investor can identify whether the asset is overbought or possesses hidden growth potential. The integration of a unique patent portfolio into these calculations confirms the company's fundamental stability.

Key competitors

tempus.com - Market Cap to Net Income|P/E Multiple QGEN|Business Payback Period Isis Pharmaceuticals|P/E Multiple RGEN (repligen.com)|Market Price to Net Income Ratio RNA (Avidity Biosciences, Inc.)|CRSP - Price to Earnings Ratio|Company Value to Net Income WGS (GeneDx)|RARE: P/E Multiple|Beam Therapeutics Corp - Company Value to Net Income|Price to Earnings Ratio SRPT|twistbioscience.com (TWST) - Business Payback Period|P/E Multiple TXG|NTLA (Intellia) - Company Value to Net Income|Price to Earnings Ratio Stoke STOK|BioLife (BLFS) - Market Cap to Earnings|wavelifesciences.com - P/E Multiple|Market Cap to Net Income MAZE|SION: P/E Multiple|PRME - Business Payback Period|Price to Earnings Ratio TSHA|QURE - Market Cap to Net Income Ratio|P/E Multiple MGTX|Business Payback Period regenxbio.com|P/E Multiple SLDB (Solid Biosciences Inc)|OCGN: Price to Earnings Multiple|PACB - Price to Earnings Ratio|Benitec (BNTC) - Price to Earnings Ratio|DSGN: P/E Multiple|RCKT: Market Price to Net Income Ratio|FDMT (4D Molecular Therapeutics, Inc.) - P/E Multiple|lexeotx.com (LXEO) - Business Payback Period|P/E Multiple KRRO|Business Payback Period Silence Therapeutics Corp|Price to Earnings Ratio proqr.com PRQR|CDXS - Price to Earnings Ratio|SGMO - Price to Earnings Ratio|Market Cap to Net Income Ratio Nautilus Biotechnology, Inc. (NAUT)|MGX: P/E Multiple|Price to Earnings Multiple DTIL|GBIO (Generation Bio) - P/E Multiple|Price to Earnings Multiple BOLD (boundlessbio.com)|Price to Earnings Ratio XCUR (exicuretx.com)|Celsion Corporation - Price to Earnings Multiple|P/E Multiple PHIO (phiopharma.com)|P/E Multiple Mustang Bio, Inc. MBIO|RNAZ: Price to Earnings Ratio|BNGO (Bionano Genomics) - Price to Earnings Multiple|APDN: P/E Multiple|bluebird bio (BLUE) - P/E Multiple|Price to Earnings Ratio ImmunoPrecise Antibodies Ltd.|Market Cap to Earnings Omega OMGA|P/E Multiple OMIC|RGLS - Market Cap to Earnings|Syros Pharmaceuticals, Inc - Price to Earnings Ratio|Business Payback Period Codex DNA (TBIO)|TCON - Price to Earnings Ratio|UBX: Price to Earnings Ratio